



Freedom of Information Request

<b>In the past 3 months, how many Breast Cancer patients (any stage) were treated with:</b>	
<b>Abemaciclib monotherapy</b>	<b>3</b>
<b>Aromatase inhibitor monotherapy (e.g. anastrozole, exemestane, letrozole)</b>	<b>0</b>
<b>Tamoxifen monotherapy</b>	<b>0</b>
<b>Abemaciclib + Tamoxifen</b>	<b>0</b>
<b>Abemaciclib + Tamoxifen + Goserelin</b>	<b>0</b>
<b>Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) + Goserelin</b>	<b>0</b>
<b>Aromatase inhibitor + Goserelin</b>	<b>0</b>
<b>Tamoxifen+ Goserelin</b>	<b>0</b>
<b>How many patients have been treated for Triple-Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:</b>	
<b>Anthracycline (e.g. doxorubicin or epirubicin) as a single agent</b>	<b>0</b>
<b>Atezolizumab +Nab-paclitaxel/Paclitaxel</b>	<b>0</b>
<b>Pembrolizumab</b>	<b>0</b>
<b>Sacituzumab Govitecan</b>	<b>0</b>
<b>Parp Inhibitors (Olaparib/Talazoparib)</b>	<b>0</b>



<b>Eribulin as a single agent or in combination</b>	<b>1</b>
<b>Capecitabine as a single agent</b>	<b>2</b>
<b>Platinum (e.g. carboplatin or cisplatin) as a single agent</b>	<b>0</b>
<b>Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent</b>	<b>5</b>
<b>Taxane and/or Anthracycline in combination</b>	<b>5</b>
<b>Any other active systemic anti-cancer therapy</b>	<b>1</b>